BR112014011316A2 - derivado de 2,5-dioxoimidazolidin-1-il-3-feniluréia como moduladores do receptor de receptor do peptídeo como formil-1 (fprl-1) - Google Patents

derivado de 2,5-dioxoimidazolidin-1-il-3-feniluréia como moduladores do receptor de receptor do peptídeo como formil-1 (fprl-1)

Info

Publication number
BR112014011316A2
BR112014011316A2 BR112014011316A BR112014011316A BR112014011316A2 BR 112014011316 A2 BR112014011316 A2 BR 112014011316A2 BR 112014011316 A BR112014011316 A BR 112014011316A BR 112014011316 A BR112014011316 A BR 112014011316A BR 112014011316 A2 BR112014011316 A2 BR 112014011316A2
Authority
BR
Brazil
Prior art keywords
receptor
fprl
dioxoimidazolidin
formyl
modulators
Prior art date
Application number
BR112014011316A
Other languages
English (en)
Inventor
E Donello John
E Garst Michael
L Beard Richard
Vu Thong
Viswanath Veena
Vuligonda Vidyasagar
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BR112014011316A2 publication Critical patent/BR112014011316A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/80—Two oxygen atoms, e.g. hydantoin with hetero atoms or acyl radicals directly attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

abstract of the disclosure the present invention relates to novel 2,5-dioxoimidazolidin-1-yl-3-phenylurea derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the n-formyl peptide receptor like-1 (fprl-1) receptor. 18945 pct (ap) tradução do resumo resumo patente de invenção: "derivado de 2,5-dioxoimidazolidin-1-il-3-feniluréia como moduladores do receptor de receptor do peptídeo como formil-1 (fprl-1)". a presente invenção refere-se aos novos derivados de 2,5-dioxoimidazolidin-1-il-3-feniluréia, processos para a sua preparação, composições farmacêuticas contendo-os e seu uso como moduladores farmacêuticos do receptor de receptor do peptídeo como formil-1 (fprl-1).
BR112014011316A 2011-11-10 2012-11-10 derivado de 2,5-dioxoimidazolidin-1-il-3-feniluréia como moduladores do receptor de receptor do peptídeo como formil-1 (fprl-1) BR112014011316A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161558080P 2011-11-10 2011-11-10
PCT/US2012/064571 WO2013071203A1 (en) 2011-11-10 2012-11-10 2,5-dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (fprl-1) receptor modulators

Publications (1)

Publication Number Publication Date
BR112014011316A2 true BR112014011316A2 (pt) 2017-05-09

Family

ID=47222328

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014011316A BR112014011316A2 (pt) 2011-11-10 2012-11-10 derivado de 2,5-dioxoimidazolidin-1-il-3-feniluréia como moduladores do receptor de receptor do peptídeo como formil-1 (fprl-1)

Country Status (13)

Country Link
US (1) US8492556B2 (pt)
EP (2) EP2776403B1 (pt)
JP (2) JP6078075B2 (pt)
KR (1) KR102271500B1 (pt)
CN (1) CN104114541A (pt)
AU (2) AU2012335039C1 (pt)
BR (1) BR112014011316A2 (pt)
CA (1) CA2855390C (pt)
DK (1) DK3103797T3 (pt)
ES (1) ES2733826T3 (pt)
RU (1) RU2645673C2 (pt)
TR (1) TR201909663T4 (pt)
WO (1) WO2013071203A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2770989T (pt) 2011-10-26 2018-12-04 Allergan Inc Derivados de amida de aminoácidos substituídos por n-ureia como moduladores de recetor tipo-1 do recetor de péptidos formil (fprl-1)
US8492556B2 (en) * 2011-11-10 2013-07-23 Allergan, Inc. 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators
CN105007909B (zh) * 2013-03-06 2019-06-28 阿勒根公司 用于治疗眼部炎性疾病的甲酰基肽受体2激动剂的用途
CA3114477A1 (en) 2013-03-06 2014-09-12 Allergan, Inc. Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
AR097279A1 (es) * 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
CN105705484B (zh) 2013-11-21 2018-09-14 阿勒根公司 作为甲酰肽受体调节剂的苯基氨基甲酸酯衍生物
ES2659156T3 (es) * 2013-11-28 2018-03-14 Kyorin Pharmaceutical Co., Ltd. Derivados de urea o sales farmacológicamente aceptables de los mismos útiles como agonistas del receptor de péptido formilado 1 (FRPL-1)
WO2015116566A1 (en) 2014-01-29 2015-08-06 Allergan, Inc. 2,5-dioxoimidazolidin-1-yl-3-urea derivatives as formyl peptide modulators
WO2015116574A1 (en) * 2014-01-29 2015-08-06 Allergan, Inc. Urea hydantoin derivatives as formyl peptide modulators
DK3145916T3 (da) * 2014-05-21 2020-05-11 Allergan Inc Imidazolderivater som formylpeptidreceptormodulatorer
SG11201704764PA (en) 2014-12-11 2017-07-28 Harvard College Inhibitors of cellular necrosis and related methods
ES2791340T3 (es) 2015-05-27 2020-11-03 Kyorin Seiyaku Kk Derivado de urea o sal farmacológicamente aceptable del mismo
PE20180234A1 (es) 2015-05-27 2018-01-31 Kyorin Seiyaku Kk Derivado de urea o sal farmacologicamente aceptable del mismo
JP2020015664A (ja) * 2016-11-21 2020-01-30 宇部興産株式会社 含窒素多環式ヘテロ環誘導体
JP7094989B2 (ja) * 2017-06-09 2022-07-04 ブリストル－マイヤーズ スクイブ カンパニー シクロプロピルウレアホルミルペプチド２受容体およびホルミルペプチド１受容体アゴニスト
LT3762380T (lt) * 2018-03-05 2022-02-25 Bristol-Myers Squibb Company Fenilpirolidinono formilpeptido 2 receptoriaus antagonistai
KR102217512B1 (ko) * 2020-07-07 2021-02-19 한화시스템 주식회사 배터리 관리 시스템을 통한 회수 요청 또는 자동 복귀를 수행하는 무인 잠수정
CN114805334B (zh) * 2022-05-24 2023-06-09 深圳大学 一种QC和GSK-3β多靶向抑制剂及其制备方法与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02011858A (es) * 2000-05-31 2004-07-30 Tanabe Seiyaku Co Inhibidores de adhesion de celula mediada por alfabeta2.
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
MXPA04000224A (es) * 2001-07-10 2005-07-25 4Sc Ag Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos.
FR2850652B1 (fr) * 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
CN1894580A (zh) * 2003-11-07 2007-01-10 阿卡蒂亚药品公司 脂氧素受体fprl1作为一种用于鉴定能有效治疗疼痛和炎症化合物的工具
WO2005087236A1 (en) * 2004-03-11 2005-09-22 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
CN100506802C (zh) * 2004-06-04 2009-07-01 中国科学院上海药物研究所 一类甲酰肽样受体-1调节剂、其制备方法和用途
US20080004282A1 (en) * 2006-04-10 2008-01-03 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
EP2217242A1 (en) * 2007-11-15 2010-08-18 Eisai R&D Management Co., Ltd. Methods of use
US8541577B2 (en) * 2011-11-10 2013-09-24 Allergan, Inc. Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators
US8492556B2 (en) * 2011-11-10 2013-07-23 Allergan, Inc. 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US8729096B2 (en) * 2012-02-16 2014-05-20 Allergan, Inc. Imidazolidine-2,4-dione derivatives as N-formyl peptide receptor 2 modulators

Also Published As

Publication number Publication date
AU2012335039A1 (en) 2014-06-05
JP6078075B2 (ja) 2017-02-08
EP3103797A1 (en) 2016-12-14
JP2017066164A (ja) 2017-04-06
CN104114541A (zh) 2014-10-22
AU2017261559A1 (en) 2017-12-07
US8492556B2 (en) 2013-07-23
AU2012335039B2 (en) 2017-08-17
CA2855390A1 (en) 2013-05-16
AU2017261559B2 (en) 2019-09-26
RU2645673C2 (ru) 2018-02-27
KR102271500B1 (ko) 2021-07-01
AU2012335039C1 (en) 2018-03-01
RU2014122753A (ru) 2015-12-20
EP3103797B1 (en) 2019-04-10
AU2017261559C1 (en) 2019-12-19
JP6392382B2 (ja) 2018-09-19
DK3103797T3 (da) 2019-07-15
EP2776403B1 (en) 2016-09-14
CA2855390C (en) 2020-08-25
WO2013071203A1 (en) 2013-05-16
ES2733826T3 (es) 2019-12-03
KR20140116379A (ko) 2014-10-02
US20130123215A1 (en) 2013-05-16
JP2014533282A (ja) 2014-12-11
EP2776403A1 (en) 2014-09-17
TR201909663T4 (tr) 2019-07-22

Similar Documents

Publication Publication Date Title
BR112014011316A2 (pt) derivado de 2,5-dioxoimidazolidin-1-il-3-feniluréia como moduladores do receptor de receptor do peptídeo como formil-1 (fprl-1)
PH12019500171A1 (en) Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators
BR112015012555A2 (pt) derivados de benzimidazol como antagonistas de ep4
MX347280B (es) Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenergicos b2 y como antagonistas muscarinicos m3.
NZ700733A (en) (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators
BR112012012261A2 (pt) compostos como moduladores de receptor com utilidade terapêutica
DOP2015000145A (es) NUEVOS DERIVADOS CARBAMATO DE CICLOHEXILO Y QUINUCLIDINILO QUE TIENEN ACTIVIDAD COMO AGONISTAS ß2 ADRENÉRGICOS Y COMO ANTAGONISTAS MUSCARÍNICOS M3
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
EA201391228A1 (ru) (ПИРИДИН-4-ИЛ)БЕНЗИЛАМИДЫ КАК АЛЛОСТЕРИЧЕСКИЕ МОДУЛЯТОРЫ АЛЬФА 7 nAChR
EA201501163A1 (ru) Модуляторы рецептора cxcr7
GEP20186911B (en) Substituted chroman compounds as calcium sensing receptor modulators
BR112016027133A8 (pt) derivados de imidazol como moduladores do receptor de formil peptídeo, composição farmacêutica e uso
BR112013012715A2 (pt) "ácidos fosfônicos como moduladores de receptores de s1p".
BR112012009670A2 (pt) compostos de cumarina como moduladores de receptor com utilidade terapêutica
EA201391710A1 (ru) Замещенные производные индола для лечения иммунологических расстройств
CO6680603A2 (es) Antagonistas no competitivos de receptores nicotínicos
IN2015MN00421A (pt)
BR112013012719A2 (pt) "compostos como moduladores de receptor com utilidade terapêutica".
BR112014001951A2 (pt) derivados de n-(imidazolidin-2-ilideno)-heterociclopenta[b]piridina como moduladores dos receptores adrenérgicos alfa 2
ECSP13013080A (es) Derivados de pirazol útiles como inhibidores de aldosterona sintasa
BR112013026507A2 (pt) derivados de metil amina fenil bicíclicos como moduladores dos receptores de esfinfgosina-1 fosfato
BR112014001938A2 (pt) derivados de n-(imidazolidin-2-ilideno) quinolina como moduladores dos receptores alfa 2 adrenérgicos
BR112013017405A2 (pt) antagonistas não competitivos do receptor nicotínico
WO2013067105A3 (en) Nicotinic receptor non-competitive modulators
ECSP12011641A (es) Derivados de amidas espirocíclicas

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired
B350 Update of information on the portal [chapter 15.35 patent gazette]